Genentech/Xoma Xanelim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Results of a second Phase III Xanelim trial, presented July 30 at the American Academy of Dermatology meeting, show that 22% of patients receiving 1 mg/kg Xanelim and 28% of patients given 2 mg/kg once weekly achieved the study's primary endpoint of a 75% or greater improvement in the Psoriasis Area Severity Index score after 12 weeks treatment vs. 5% of placebo patients. The trial enrolled 597 patients with moderate to severe plaque psoriasis. A second 12-week course of treatment in 134 partial responders resulted in a 75% or greater improvement in PASI score for 58% of patients receiving Xanelim 2 mg/kg weekly and 29% for those receiving 2 mg/kg every other week vs. 4% for placebo. Genentech aims "ultimately to position [efalizumab] for chronic and/or maintenance therapy" of psoriasis, Genentech Product Development Head Bernice Welles, MD, said during a July 31 conference call. Results of the firm's first pivotal trial were presented June 21 (Pharmaceutical Approvals Monthly, July 2001, p. 21)
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.